Sector
PharmaceuticalsOpen
₹2,056.25Prev. Close
₹2,056.25Turnover(Lac.)
₹17,261.13Day's High
₹2,074.9Day's Low
₹2,00152 Week's High
₹2,402.952 Week's Low
₹1,493.3Book Value
₹488.78Face Value
₹2Mkt Cap (₹ Cr.)
92,718.26P/E
31.28EPS
65.7Divi. Yield
0.399 Jul 2024
12:00 AM
AGM
Announcement Date: 09 Jul, 2024
22 Oct 2024
12:00 AM
Board Meeting
Agenda : Audited Result
6 May 2024
12:00 AM
Dividend
Dividend Amount: 8
Record Date: 16 Jul, 2024
Here are some of the stocks that may see significant price movement today: Tata Motors, BHEL, Hindalco, Lupin, etc.
Lupin was already selling Huminsulin under the license agreement entered with Lilly India.
The approval enables Lupin to offer a generic version of Descovy pills, which were originally produced by Gilead Sciences Inc.
Here are some of the stocks that may see significant price movement today: Reliance Industries, Biocon, Bharat Forge, etc.
Lupin ranks as the third-largest pharmaceutical player in the U.S. by prescriptions and seventh in the Indian Pharmaceutical Market (IPM).
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 91.22 | 91 | 90.9 | 90.79 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 20,511.87 | 18,320.86 | 18,059.29 | 18,474.78 |
Net Worth | 20,603.09 | 18,411.86 | 18,150.19 | 18,565.57 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 11,771.67 | 11,055.93 | 11,025.66 | 10,080.58 |
yoy growth (%) | 6.47 | 0.27 | 9.37 | -20.16 |
Raw materials | -4,467.26 | -4,182.31 | -4,207.27 | -3,474.35 |
As % of sales | 37.94 | 37.82 | 38.15 | 34.46 |
Employee costs | -1,918.16 | -1,695.86 | -1,703.22 | -1,441.64 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | -161.53 | 1,629.7 | 1,811.46 | 1,793.93 |
Depreciation | -514.19 | -502.83 | -518.75 | -389.81 |
Tax paid | -27.17 | -371.08 | -324.7 | -449.27 |
Working capital | -135.75 | -894.67 | -203.16 | 1,003.92 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 6.47 | 0.27 | 9.37 | -20.16 |
Op profit growth | -89.76 | 7.15 | -8.54 | -53.5 |
EBIT growth | -105.27 | -10.39 | 2.01 | -56.58 |
Net profit growth | -114.99 | 72.99 | -45.89 | -57.19 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 19,656.34 | 16,269.98 | 16,192.79 | 14,926.99 | 15,142.8 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 19,656.34 | 16,269.98 | 16,192.79 | 14,926.99 | 15,142.8 |
Other Operating Income | 354.48 | 371.68 | 212.69 | 235.97 | 231.96 |
Other Income | 120.17 | 73.36 | 142.05 | 137.62 | 617.8 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,742.2 | 151.67 | 4,18,132.11 | 1,181.05 | 0.77 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,618.55 | 81.25 | 1,49,254.4 | 518 | 0.53 | 2,302 | 513.62 |
Cipla Ltd CIPLA | 1,439.5 | 24.95 | 1,16,122.78 | 1,438.15 | 0.9 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,207.7 | 59.46 | 1,08,471.97 | 485 | 0.87 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,481.6 | 52.93 | 1,02,347.53 | 416.38 | 0 | 2,396.57 | 334.18 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman (Non-Executive)
M D Gupta
Managing Director
Nilesh Deshbandhu Gupta.
Director & Chief Executive Off
Vinita Gupta
Company Sec. & Compli. Officer
R V Satam
Independent Director
Jean-Luc Belingard
Executive Director & CFO
Ramesh Swaminathan
Independent Director
Mark D McDade
Independent Director
K B S Anand
Independent Director
Punita Kumar Sinha
Independent Director
Jeffrey Kindler
Independent Director
Alfonso Zulueta
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Lupin Ltd
Summary
Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The Company has significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, Central Nervous System (CNS), Gastro-Intestinal (GI), Anti-Infective and Nonsteroidal Anti Inflammatory Drug (NSAID) therapy segments and is a global leader in the Anti-TB and Cephalosporins segments.Lupin Ltd was incorporated in the year 1983 with the name Lupin Chemicals Ltd. In the year 1987, the company commenced operations in Cephalexin Plant at Mandideep and 7 ADCA plant at Ankleshwar. In the year 1989, the company established a joint venture in Thailand, namely Lupin Chemicals (Thailand) Ltd. In the year 1991, they initiated production of Injectable cephalosporin (bulk and dosages) at Mandideep. In the year 1992, the company set up Fermentation Plant at Tarapur, Maharashtra. Also, Sterile Plant for injectable Cephalosporins (bulk) was commissioned at Mandideep.In the year 2001, Lupin Laboratories Ltd was amalgamated with the company and the name was changed to Lupin Ltd. They commenced supply of Cephalosporin bulk actives to their alliance partners in the US. Also, they commissioned a state of the art US FDA approvable oral cephalosporin bulk active plant. In the year 2002, the company commissioned the new Anti-TB facility at Aurangabad. In the year 2003, the
Read More
What is the Lupin Ltd share price today?
The Lupin Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹2032.25 today.
What is the Market Cap of Lupin Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Lupin Ltd is ₹92718.26 Cr. as of 03 Feb ‘25
What is the PE and PB ratio of Lupin Ltd?
The PE and PB ratios of Lupin Ltd is 31.28 and 4.27 as of 03 Feb ‘25
What is the 52 Week High and Low of Lupin Ltd?
The 52-week high/low is the highest and lowest price at which a Lupin Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Lupin Ltd is ₹1493.3 and ₹2402.9 as of 03 Feb ‘25
What is the CAGR of Lupin Ltd?
Lupin Ltd's CAGR for 5 Years at 23.76%, 3 Years at 31.51%, 1 Year at 35.84%, 6 Month at 5.27%, 3 Month at -6.44% and 1 Month at -13.05%.
What is the shareholding pattern of Lupin Ltd?
The shareholding pattern of Lupin Ltd is as follows:
Promoters - 46.95 %
Institutions - 46.79 %
Public - 6.26 %
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
